These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 12874031)
1. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Lozano J; Xing R; Cai Z; Jensen HL; Trempus C; Mark W; Cannon R; Kolesnick R Cancer Res; 2003 Jul; 63(14):4232-8. PubMed ID: 12874031 [TBL] [Abstract][Full Text] [Related]
2. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity. Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786 [TBL] [Abstract][Full Text] [Related]
3. Solution structure and functional analysis of the cysteine-rich C1 domain of kinase suppressor of Ras (KSR). Zhou M; Horita DA; Waugh DS; Byrd RA; Morrison DK J Mol Biol; 2002 Jan; 315(3):435-46. PubMed ID: 11786023 [TBL] [Abstract][Full Text] [Related]
4. PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Yao D; Alexander CL; Quinn JA; Porter MJ; Wu H; Greenhalgh DA Cancer Res; 2006 Feb; 66(3):1302-12. PubMed ID: 16452183 [TBL] [Abstract][Full Text] [Related]
5. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Casanova ML; Larcher F; Casanova B; Murillas R; Fernández-Aceñero MJ; Villanueva C; Martínez-Palacio J; Ullrich A; Conti CJ; Jorcano JL Cancer Res; 2002 Jun; 62(12):3402-7. PubMed ID: 12067982 [TBL] [Abstract][Full Text] [Related]
7. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Ulkü AS; Schäfer R; Der CJ Mol Cancer Res; 2003 Dec; 1(14):1077-88. PubMed ID: 14707291 [TBL] [Abstract][Full Text] [Related]
8. Characterization of kinase suppressor of Ras-1 expression and anticancer drug sensitivity in human cancer cell lines. Stoeger SM; Cowan KH Cancer Chemother Pharmacol; 2009 Apr; 63(5):807-18. PubMed ID: 18661133 [TBL] [Abstract][Full Text] [Related]
9. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089 [TBL] [Abstract][Full Text] [Related]
10. CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Ritt DA; Zhou M; Conrads TP; Veenstra TD; Copeland TD; Morrison DK Curr Biol; 2007 Jan; 17(2):179-84. PubMed ID: 17174095 [TBL] [Abstract][Full Text] [Related]
11. 12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mouse epidermis coexpressing transforming growth factor-alpha and v-fos: acceleration of autonomous papilloma formation and malignant conversion via c-Ha-ras activation. Wang XJ; Liefer KM; Greenhalgh DA; Roop DR Mol Carcinog; 1999 Dec; 26(4):305-11. PubMed ID: 10569807 [TBL] [Abstract][Full Text] [Related]
12. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849 [TBL] [Abstract][Full Text] [Related]
13. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation. Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717 [TBL] [Abstract][Full Text] [Related]
14. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. Liu X; Lee J; Cooley M; Bhogte E; Hartley S; Glick A Cancer Res; 2003 Nov; 63(22):7760-8. PubMed ID: 14633701 [TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of the epidermal growth factor receptor impairs growth of squamous papillomas expressing the v-ras(Ha) oncogene but does not block in vitro keratinocyte responses to oncogenic ras. Dlugosz AA; Hansen L; Cheng C; Alexander N; Denning MF; Threadgill DW; Magnuson T; Coffey RJ; Yuspa SH Cancer Res; 1997 Aug; 57(15):3180-8. PubMed ID: 9242447 [TBL] [Abstract][Full Text] [Related]
16. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339 [TBL] [Abstract][Full Text] [Related]
17. Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras. Tokumitsu Y; Nakano S; Ueno H; Niho Y J Cell Physiol; 2000 May; 183(2):221-7. PubMed ID: 10737897 [TBL] [Abstract][Full Text] [Related]
18. Transgenic coexpression of v-Ha-ras and transforming growth factor alpha increases epidermal hyperproliferation and tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras activation. Wang XJ; Greenhalgh DA; Roop DR Mol Carcinog; 2000 Mar; 27(3):200-9. PubMed ID: 10708482 [TBL] [Abstract][Full Text] [Related]
19. c-Jun NH2-terminal kinase 2 is required for Ras transformation independently of activator protein 1. Nielsen C; Thastrup J; Bøttzauw T; Jäättelä M; Kallunki T Cancer Res; 2007 Jan; 67(1):178-85. PubMed ID: 17210697 [TBL] [Abstract][Full Text] [Related]
20. Vav transformation requires activation of multiple GTPases and regulation of gene expression. Palmby TR; Abe K; Karnoub AE; Der CJ Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]